| scholarly article | Q13442814 |
| P50 | author | Giorgio Bernardi | Q110496108 |
| Diego Centonze | Q42218235 | ||
| P2093 | author name string | Mauro Maccarrone | |
| Monica Bari | |||
| Paolo Calabresi | |||
| Diego Centonze | |||
| Paolo Gubellini | |||
| Barbara Picconi | |||
| Alessandro Finazzi-Agrò | |||
| Natalia Battista | |||
| P2860 | cites work | Molecular cloning of a human cannabinoid receptor which is also expressed in testis | Q24337626 |
| Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase | Q24555807 | ||
| The effects of cannabinoids on the brain | Q28137626 | ||
| Addiction, dopamine, and the molecular mechanisms of memory | Q28142501 | ||
| Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons | Q28245016 | ||
| Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist | Q28262546 | ||
| Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1 | Q28270721 | ||
| Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides | Q28295481 | ||
| Methyl arachidonyl fluorophosphonate: a potent irreversible inhibitor of anandamide amidase | Q28305612 | ||
| Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons | Q28363375 | ||
| Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study | Q72656516 | ||
| Dopamine receptors and groups I and II mGluRs cooperate for long-term depression induction in rat prefrontal cortex through converging postsynaptic activation of MAP kinases | Q73176523 | ||
| Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor | Q73704501 | ||
| Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors | Q74061522 | ||
| Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide | Q28370516 | ||
| Age dependent accumulation of N-acyl-ethanolamine phospholipids in ischemic rat brain. A (31)P NMR and enzyme activity study | Q28566271 | ||
| Facilitated glutamatergic transmission in the striatum of D2 dopamine receptor-deficient mice | Q28590689 | ||
| Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study | Q29615905 | ||
| CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum | Q31817073 | ||
| Structural determinants for recognition and translocation by the anandamide transporter | Q33861497 | ||
| The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. | Q33930416 | ||
| The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors | Q33940288 | ||
| Electrophysiology of dopamine in normal and denervated striatal neurons | Q34070888 | ||
| Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism | Q34070904 | ||
| 2-Arachidonoylglycerol and the cannabinoid receptors | Q34098975 | ||
| The fatty acid amide hydrolase (FAAH). | Q34098981 | ||
| The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes | Q34098988 | ||
| N-Acylethanolamines and precursor phospholipids - relation to cell injury | Q34098995 | ||
| Dopaminergic control of synaptic plasticity in the dorsal striatum | Q34206258 | ||
| Modulation of transmitter release via presynaptic cannabinoid receptors | Q34430714 | ||
| Pharmacology of cannabinoid CB1 and CB2 receptors. | Q34442847 | ||
| Dopamine-dependent synaptic plasticity in striatum during in vivo development | Q34658296 | ||
| Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system | Q34745063 | ||
| Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells | Q37599138 | ||
| Cannabinoid pharmacology | Q39741984 | ||
| Pharmacology of cannabinoid receptors | Q40437020 | ||
| The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism | Q40817229 | ||
| Role of cyclic AMP in the actions of cannabinoid receptors | Q41090638 | ||
| The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments | Q41277031 | ||
| The neostriatum beyond the motor function: experimental and clinical evidence | Q41458161 | ||
| Dopamine activation of endogenous cannabinoid signaling in dorsal striatum | Q41646203 | ||
| Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains | Q42490661 | ||
| Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease | Q42497576 | ||
| Localization of cannabinoid receptor mRNA in rat brain | Q42510202 | ||
| Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease | Q43504648 | ||
| Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum. | Q43621342 | ||
| Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine. | Q43662825 | ||
| Anandamide degradation and N-acylethanolamines level in wild-type and CB1 cannabinoid receptor knockout mice of different ages | Q43681018 | ||
| Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration | Q43752352 | ||
| Influence of phenylmethylsulfonyl fluoride on anandamide brain levels and pharmacological effects | Q44875896 | ||
| P42/44 MAP kinase inhibitor PD98059 attenuates multiple forms of synaptic plasticity in rat dentate gyrus in vitro | Q48302211 | ||
| Anandamide hydrolysis by human cells in culture and brain | Q48346766 | ||
| Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion | Q48653795 | ||
| Activation of inwardly rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes | Q49065140 | ||
| Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial characterization | Q72631582 | ||
| P433 | issue | 16 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| striatum | Q1319792 | ||
| parkinsonian syndrome | Q1531991 | ||
| endocannabinoids | Q10483908 | ||
| P304 | page(s) | 6900-6907 | |
| P577 | publication date | 2002-08-01 | |
| P1433 | published in | Journal of Neuroscience | Q1709864 |
| P1476 | title | Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission | |
| P478 | volume | 22 |
| Q44853701 | A critical interaction between dopamine D2 receptors and endocannabinoids mediates the effects of cocaine on striatal gabaergic Transmission |
| Q41260178 | A novel crosstalk within the endocannabinoid system controls GABA transmission in the striatum. |
| Q42523780 | Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum |
| Q36248857 | Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. |
| Q90217765 | Behavioral effects of psychostimulants in mutant mice with cell-type specific deletion of CB2 cannabinoid receptors in dopamine neurons |
| Q35166600 | Biosynthesis of endocannabinoids and their modes of action in neurodegenerative diseases |
| Q30833645 | Brain morphometry and the neurobiology of levodopa-induced dyskinesias: current knowledge and future potential for translational pre-clinical neuroimaging studies. |
| Q84093381 | Cannabinoid CB1 receptors are early downregulated followed by a further upregulation in the basal ganglia of mice with deletion of specific park genes |
| Q37734568 | Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. |
| Q38522769 | Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia |
| Q36155898 | Cannabinoids and Dementia: A Review of Clinical and Preclinical Data |
| Q36977766 | Cannabinoids and neuroprotection in basal ganglia disorders. |
| Q91934280 | Cannabinoids and the expanded endocannabinoid system in neurological disorders |
| Q38563981 | Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications |
| Q42258332 | Cannabinoids in Parkinson's Disease |
| Q38269376 | Cannabinoids: new promising agents in the treatment of neurological diseases |
| Q34549222 | Cannabis and cannabinoid receptors: from pathophysiology to therapeutic options |
| Q35217244 | Cellular accumulation of anandamide: consensus and controversy |
| Q48515330 | Ciliary neurotrophic factor activates astrocytes, redistributes their glutamate transporters GLAST and GLT-1 to raft microdomains, and improves glutamate handling in vivo. |
| Q44455990 | Comparative analysis of fatty acid amide hydrolase and cb(1) cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling |
| Q36618364 | Comparative effects of parathion and chlorpyrifos on endocannabinoid and endocannabinoid-like lipid metabolites in rat striatum |
| Q26830147 | Deep brain stimulation: are astrocytes a key driver behind the scene? |
| Q37185190 | Differential striatal spine pathology in Parkinson's disease and cocaine addiction: a key role of dopamine? |
| Q30498354 | Differential structural plasticity of corticostriatal and thalamostriatal axo-spinous synapses in MPTP-treated Parkinsonian monkeys |
| Q38234309 | Direct and indirect pathways of basal ganglia: a critical reappraisal |
| Q34104954 | Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure |
| Q35138420 | Dopamine regulates distinctively the activity patterns of striatal output neurons in advanced parkinsonian primates |
| Q35828317 | Dopamine-dependent corticostriatal synaptic filtering regulates sensorimotor behavior |
| Q38722989 | Dysregulation of striatal projection neurons in Parkinson's disease |
| Q37778901 | Effects of GPi and STN inactivation on physiological, motor, cognitive and motivational processes in animal models of Parkinson's disease |
| Q42408299 | Effects of SR141716A on Cognitive and Depression-Related Behavior in an Animal Model of Premotor Parkinson's Disease. |
| Q48428879 | Effects of endocannabinoid neurotransmission modulators on brain stimulation reward |
| Q44597458 | Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa‐induced dyskinesias |
| Q38018946 | Endocannabinoid modulation of dopaminergic motor circuits. |
| Q34967151 | Endocannabinoid signaling in midbrain dopamine neurons: more than physiology? |
| Q39368845 | Endocannabinoid system in neurodegenerative disorders. |
| Q30391852 | Endocannabinoid system: emerging role from neurodevelopment to neurodegeneration |
| Q42508054 | Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models |
| Q38593124 | Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others |
| Q36686382 | Endocannabinoids in striatal plasticity |
| Q43064653 | Evaluation of the role of striatal cannabinoid CB1 receptors on movement activity of parkinsonian rats induced by reserpine |
| Q44793025 | Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: a modulator of endocannabinoid function |
| Q42520647 | Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. |
| Q82029286 | Functional neurochemistry of the basal ganglia |
| Q50200300 | Functional relevance of endocannabinoid-dependent synaptic plasticity in the CNS. |
| Q49246060 | Glutamatergic Tuning of Hyperactive Striatal Projection Neurons Controls the Motor Response to Dopamine Replacement in Parkinsonian Primates |
| Q24814542 | Harm reduction--the cannabis paradox |
| Q37213655 | Human striatal recordings reveal abnormal discharge of projection neurons in Parkinson's disease. |
| Q33751118 | In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liability |
| Q41832173 | Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors |
| Q35932567 | Inversion of dopamine responses in striatal medium spiny neurons and involuntary movements |
| Q41911434 | Involvement of 2-arachidonoyl glycerol in the increased consumption of and preference for ethanol of mice treated with neurotoxic doses of methamphetamine |
| Q46384445 | Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. |
| Q80065578 | Levels of N-acylethanolamines in human tumors: in search of reliable data |
| Q38766091 | Loss and remodeling of striatal dendritic spines in Parkinson's disease: from homeostasis to maladaptive plasticity? |
| Q36861976 | Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat. |
| Q35168593 | Manipulation of the endocannabinoid system by a general anaesthetic |
| Q37512670 | Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy. |
| Q58102489 | Medical Use of Cannabinoids |
| Q48393298 | Metabolic changes detected by ex vivo high resolution 1H NMR spectroscopy in the striatum of 6-OHDA-induced Parkinson's rat. |
| Q36374309 | Metabotropic glutamate receptor 4 in the basal ganglia of parkinsonian monkeys: ultrastructural localization and electrophysiological effects of activation in the striatopallidal complex |
| Q54527239 | Miniature synaptic events elicited by presynaptic Ca2+ rise are selectively suppressed by cannabinoid receptor activation in cerebellar Purkinje cells. |
| Q40430558 | Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, L-DOPA Responsivity, and Glutamatergic Neurotransmission. |
| Q27014154 | Modulation of the endocannabinoid system: vulnerability factor and new treatment target for stimulant addiction |
| Q37132571 | Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2 |
| Q35176103 | Neuroglial plasticity at striatal glutamatergic synapses in Parkinson's disease |
| Q30493991 | Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity. |
| Q92535276 | Neuroprotective Effect of AM404 Against NMDA-Induced Hippocampal Excitotoxicity |
| Q42455192 | New insights into the organization of the basal ganglia |
| Q36074595 | New insights on endocannabinoid transmission in psychomotor disorders |
| Q41809772 | Nigrostriatal denervation changes the effect of cannabinoids on subthalamic neuronal activity in rats. |
| Q36775237 | Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis |
| Q33714587 | Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications |
| Q44535579 | Perinatal exposure to delta 9-tetrahydrocannabinol increases presynaptic dopamine D2 receptor sensitivity: a behavioral study in rats |
| Q38099828 | Perspective: Identification of genetic variants associated with dopaminergic compensatory mechanisms in early Parkinson's disease |
| Q35499568 | Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection |
| Q36961171 | Roles of transient receptor potential vanilloid subtype 1 and cannabinoid type 1 receptors in the brain: neuroprotection versus neurotoxicity |
| Q46896175 | Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. |
| Q34547533 | Stage-variations of anandamide hydrolase activity in the mouse uterus during the natural oestrus cycle |
| Q34416203 | Striatal spine plasticity in Parkinson's disease |
| Q42525242 | Substance P depolarizes striatal projection neurons and facilitates their glutamatergic inputs |
| Q35193305 | Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease |
| Q52371217 | Synaptic plasticity and levodopa-induced dyskinesia: electrophysiological and structural abnormalities. |
| Q37150745 | Targeting the endocannabinoid system: to enhance or reduce? |
| Q35014951 | Temporal changes of CB1 cannabinoid receptor in the basal ganglia as a possible structure-specific plasticity process in 6-OHDA lesioned rats. |
| Q40628674 | The CB1/VR1 agonist arvanil induces apoptosis through an FADD/caspase-8-dependent pathway |
| Q60715991 | The Distinct Role of Medium Spiny Neurons and Cholinergic Interneurons in the D2/A2A Receptor Interaction in the Striatum: Implications for Parkinson's Disease |
| Q64760299 | The Modulation of Pain by Metabotropic Glutamate Receptors 7 and 8 in the Dorsal Striatum |
| Q61804251 | The Role of Lipids in Parkinson's Disease |
| Q37376434 | The biosynthesis of N-arachidonoyl dopamine (NADA), a putative endocannabinoid and endovanilloid, via conjugation of arachidonic acid with dopamine |
| Q35740152 | The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats |
| Q34267133 | The decrease of dopamine D₂/D₃ receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB₁ cannabinoid receptors in Parkinson's disease: a preliminary autoradiographic study with the selective dopamine D₂/D₃ an |
| Q36630516 | The endocannabinoid 2-arachidonoylglycerol mediates D1 and D2 receptor cooperative enhancement of rat nucleus accumbens core neuron firing |
| Q37394164 | The endocannabinoid system as a target for the treatment of motor dysfunction |
| Q34098196 | The endocannabinoid system as a target for the treatment of neurodegenerative disease |
| Q24648473 | The endocannabinoid system as an emerging target of pharmacotherapy |
| Q38156518 | The influence of cannabinoids on generic traits of neurodegeneration |
| Q35171113 | The therapeutic potential of cannabinoids for movement disorders |
| Q36341688 | The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids |
| Q45230637 | Transient receptor potential vanilloid subtype 1 mediates cell death of mesencephalic dopaminergic neurons in vivo and in vitro. |
Search more.